Oncology-focused digital therapeutics firm Mika Well being introduced a partnership with pharma corporations AstraZeneca and Daiichi Sankyo for an initiative dubbed “UNITE” to offer digital therapeutics to ladies present process breast most cancers therapies.
Mika Well being’s app provides most cancers sufferers entry to psychological assist to cut back disease-related nervousness, melancholy and stress. Sufferers can observe unintended effects from medicines, obtain remedy reminders, receive schooling and diet recommendation, and coordinate appointments.
The digital therapeutic, already licensed as a medical gadget and launched within the EU, could be personalised to a person’s particular sort of most cancers.
By means of the partnership, Mika Well being’s choices shall be used alongside pharmaceutical remedy.
German-speaking sufferers in Switzerland can first entry the providing, after which the businesses will increase to incorporate Switzerland’s French- and Italian-speaking areas.
“Digital therapies have gotten more and more necessary in trendy most cancers therapy,” Adam Nosal, head of oncology at AstraZeneca Switzerland, mentioned in a press release. “This partnership with Mika permits us to increase entry to holistic most cancers care and acquire insights that may form our broader efforts to enhance therapeutic choices for most cancers sufferers.”
THE LARGER TREND
In June, Mika Well being and the worldwide nonprofit Most cancers Assist Group introduced they are going to present an AI-enabled oncology-focused digital therapeutic for U.S.-based most cancers sufferers and their caregivers to entry psychological well being and different assist companies freed from cost.
Earlier this 12 months, the corporate introduced a partnership with AI oncology agency Large Bio to offer free entry to Miko’s choices by Large Bio’s platform.
Mika sufferers would even be given the power to take part in Large’s AI-enabled biomarker testing and medical trial matching choices.
The HIMSS AI in Healthcare Discussion board is scheduled to happen September 5-6 in Boston. Study extra and register.
